These apoB38.9 mutant mice may be useful to study the genetic and molecular mechanism of apoB defects and lipid metabolism/liver fat accumulation, the relationship between hepatic steatosis and insulin resistance, the progression of advanced non-alcoholic fatty liver diseases (NAFLD), and atherosclerosis. In addition, all three congenic apoB38.9 strains (Stock No. 007679, Stock No. 007682, and Stock No. 007683) may be useful in conjunction with other apoB mutant mice, including Stock No. 002053 (apoB70), Stock No. 002876 (apoB48-only), and Stock No. 002877 (apoB100-only).
Gustav Schonfeld, Washington University School of Medicine
Mice homozygous for this apoB38.9 allele (apoB38.9/38.9) are viable with impaired fertility, bearing a premature stop codon at residue 1767 of the targeted gene. As a result, homozygous plasma shows a truncated apoB38.9 as the sole apoB protein. Plasma from heterozygous (apoB+/38.9) mice have reduced apoB100 and apoB48 compared to wildtype, with apoB38.9 representing 20% of total circulating apoB. This apoB38.9 truncation affects both apoB100 and apoB48 metabolism in mice, and mimics human Familial Hypobetalipoproteinemia (FHBL). Homozygous and, to a lesser extent, heterozygous mice exhibit symptoms of FHBL due to impaired lipoprotein export system/VLDL secretion, including elevated hepatic triglyceride (TG), cholesterol and free fatty acids (FFA), with decreased plasma TG and cholesterol. Because plasma and liver lipid profiles range from mild to severe in populations of heterozygous apoB38.9 mice on a mixed (C57BL/6J;129X1/SvJ) genetic background, apoB+/38.9 congenic mice were generated on three different inbred strains with characterized differences in liver fat: SWR/J (low liver TG strain, ~40mg/dL), C57BL/6J (medium liver TG, ~140mg/dL), and BALB/cByJ (high liver TG strain, ~200 mg/dL). All three apoB+/38.9 congenic strains exhibit significantly impaired hepatic TG secretion compared to their respective genetic backgrounds, with significant interactions observed between genetic background and apoB genotype for liver TG and FFA. BALB/cByJ-apoB38.9 mice (Stock No. 007683) exhibit the greatest hepatic TG and FFA increase (probably due to elevated hepatic TG synthesis rate). Despite having the lowest degree of hepatic steatosis among the three apoB+/38.9 congenic strains, SWR/J-apoB38.9 mice (Stock No. 007679) show insulin resistance, with BALB/cByJ-apoB38.9 mice exhibiting intermediate and C57BL/6J-apoB38.9 mice (Stock No. 007682) exhibiting the greatest insulin resistance. Additional comparisons between the three congenic strains reveal that C57BL/6J-apoB38.9 mice have significant increase of fatty acid synthesis rate compared to the other two congenic strains, while SWR/J-apoB38.9 mice show dynamic feedback regulation of fatty acids and TG synthesis and beta-oxidation in response to excessive hepatic TG accumulation. Gender dimorphism is observed; while BALB/cByJ-apoB38.9 males have reduced plasma cholesterol levels compared to wildtype males, females from all three apoB+/38.9 congenic strains have reduced plasma cholesterol compared to wildtype females. Male BALB/cByJ-apoB38.9 and C57BL/6J-apoB38.9 mice have significant reduction of liver TG synthesis compared to wildtype males, while SWR/J-apoB38.9 females show the same significant reduction. These apoB38.9 mutant mice may be useful to study the genetic and molecular mechanism of apoB defects and lipid metabolism/liver fat accumulation, the relationship between hepatic steatosis and insulin resistance, the progression of advanced non-alcoholic fatty liver diseases (NAFLD), and atherosclerosis. These apoB38.9 mutant mice may also be useful in conjunction with other apoB mutant mice, including Stock No. 002053 (apoB70), Stock No. 002876 (apoB48-only), and Stock No. 002877 (apoB100-only).
A targeting vector was designed (by site-directed mutagenesis) to delete nucleotide 5449 of the mouse apo B cDNA sequence (the deletion is predicted to produce a premature stop codon at the same position (i.e. residue 1767) as that occurring in the apo B-38.9 mutation of human familial hypobetalipoproteinemia (FHBL) subjects). This also inserted a loxP-flanked PGK-neo cassette within intron 24. The construct was electroporated into 129X1/SvJ-derived RW4 embryonic stem (ES) cells. Correctly targeted ES cells were transiently transfected with a Cre-expressing vector to remove the selection cassette (leaving a single loxP site in intron 24) and then injected into C57BL/6 blastocysts. The resulting chimeric males were bred to C57BL/6 females. Heterozygotes were then backcrossed to SWR/J inbred mice (see Stock No. 000689) for 8 generations prior to arrival at The Jackson Laboratory.
|Allele Name||targeted mutation 1.1, Zhouji Chen|
|Allele Type||Targeted (Humanized sequence)|
|Allele Synonym(s)||Apobtm1.1Zc; targeted mutation 1.1, Zhouji Chen|
|Gene Symbol and Name||Apob, apolipoprotein B|
|Gene Synonym(s)||expressed sequence AI315052; FLDB; ApoB-100; Ac1-060; Apo B-100; AI315052; LDLCQ4; ApoB-48; Aa1064; apob-48; apob-100; apoB-100; apoB-48|
|Promoter||Apob, apolipoprotein B, mouse, laboratory|
|Strain of Origin||129X1/SvJ|
|Molecular Note||Deletion of nucleotide 5449 in exon 26 and a loxP-flanked PGK-neo cassette inserted into intron 24 were introduced to the gene via homologous recombination. This deletion mimics the ApoB-38.9 truncation mutation found in human familial hypobetalipoproteinemia (FHBL). The neo cassette was removed by transient expression of Cre recombinase in correctly targeted ES cells. Southern blot analysis confirmed the absence of the neo cassette in homozygous mutant mice; Western blot analysis showed a mutant protein product of similar size to the human ApoB-38.9 mutant protein.|
|Mutations Made By|| |
Zhouji Chen, Washington University School of Medicine
When maintaining a live colony, heterozygotes are bred to wildtype siblings or to SWR/J inbred mice (see Stock No. 000689). The donating investigator reports that homozygous mice are produced in reduced rates and are probably infertile.
When using the SWR.129X1(B6)-Apobtm1.1Zc/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #007679 in your Materials and Methods section.
|Heterozygous or Wild-Type for Apob<tm1.1Zc>|
We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.
Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.
MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.
Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.